MarketLens

Log in

Vertex's Casgevy Pediatric Approval: A $2.2 Million Bet on Gene-Editing Dominance

3 hours ago
SHARE THIS ON:

Vertex's Casgevy Pediatric Approval: A $2.2 Million Bet on Gene-Editing Dominance

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News1 day ago

Sionna Therapeutics: NBD1 Stabilization Could Redefine Cystic Fibrosis Treatment

Sionna Therapeutics' NBD1 stabilization approach could enhance CFTR function beyond current CF standards. SION-719 and SION-451 face pivotal readouts in summer 2026. A $289.9M cash runway through 2028...
Stock News2 weeks ago

Rocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million

Rocket Pharmaceuticals closed the sale of its Rare Pediatric Disease PRV for $180 million gross proceeds, granted by the FDA in March 2026 for KRESLADI approval.
Stock News2 weeks ago

Vertex Says Pediatric CASGEVY Data Show Consistent Benefits In Rare Blood Disorders

Vertex reported CASGEVY data showing sustained benefits in children with sickle cell disease and beta thalassemia, reinforcing the therapy's profile in rare blood disorders.
Stock News4 weeks ago

Eli Lilly Just Proved Gene Editing Could Be Pharma's Next Gold Rush -- but CRISPR Therapeutics Investors Should Watch Out

Eli Lilly reported positive clinical trial results for a new gene-editing candidate, signaling potential competition for CRISPR Therapeutics. This development highlights the growing commercial viabili...

Breaking News

View All →

Top Headlines

View More →
Stock News42 minutes ago

The Neocloud Trade Could Turn Shareholders Into Bagholders. Nebius Just Cratered 17%

Stock News53 minutes ago

Tesla's Electric Semi Has Its First Fatal Crash

Stock News1 hour ago

Apple (AAPL) Rises As Market Takes a Dip: Key Facts

Stock News1 hour ago

Amazon (AMZN) Gains As Market Dips: What You Should Know

Stock News1 hour ago

Alphabet Inc. (GOOG) Advances While Market Declines: Some Information for Investors